Shanghai Henlius Biotech Receives NMPA Approval for HLX701 Phase 1b/2 Clinical Trial Application
I'm PortAI, I can summarize articles.
Shanghai Henlius Biotech Inc. has received approval from the National Medical Products Administration for its IND application for a phase 1b/2 clinical trial of HLX701, a recombinant human SIRPα-IgG4 Fc fusion protein injection, aimed at treating advanced colorectal cancer. This marks a significant step as no SIRPα-Fc fusion protein targeting CD47 has been approved globally. However, the company cautions that successful development and commercialization of HLX701 is not guaranteed, advising shareholders and potential investors to exercise caution.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments